tol-101
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2010 (NCT01154387)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- T cell receptor beta constant 1INHIBITOR
TRBC1 inhibitor
- T-cell receptorINHIBITOR
T-cell receptor inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS28X0AGG6P8 ↗
- ChEMBLCHEMBL2109591 ↗
Also known as
- tol101
- tol-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01154387 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2010 | Tolera Therapeutics, Inc, University of Rochester |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tolera Therapeutics, Inc | For profit | 1 | 1 | 1 | 2010 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1